Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab in refractory generalized myasthenia gravis in Chinese patients
NCT06764160Phase 3Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jan 2025
- Primary completion
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of eculizumab in myasthenia gravis (MG), sponsored by Alexion Pharmaceuticals. Started Jan 2025; status: completed.
02
Drugs
eculizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT06764160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06764160.